The cellular biology of B-cell chronic lymphocytic leukemia

Critical Reviews in Oncology/Hematology

Volumn 27, Issue 1, 1998, Pages 29-52

  Jurlander, Jesper ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BASIC FIBROBLAST GROWTH FACTOR; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CD5 ANTIGEN; CD81 ANTIGEN; CHEMOKINE RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; CYTOKINE RECEPTOR; INTERFERON RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LYMPHOCYTE RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; AUTOIMMUNITY; B CELL LEUKEMIA; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TRISOMY;

EID: 0031800816     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)10008-7     Document Type: Article

References (266)

1. [1] Dameshek W. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood 1967;29:566-83.
2. [2] Cheson BD, Bennet JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
3. [3] Schroeder HW, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15:288-94.
4. [4] Hardy RR, Hayakawa K. CD5 B-cells, a fetal B-cell lineage. Adv Immunol 1994;55:297-339.
5. [5] Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B-cells. Blood 1996;87:2615-20.
6. [6] Jurlander J, Lai CF, Tan J, et al. Characterization of IL-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 1997;89:4146-52.
7. INK4/CDKN2 and cyclin D1 co-operate to deregulate G1 control. Cancer Res 1995;55:4818-23.
8. [8] Liu Y, Szekely L, Grander D, et al. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: evidence for a role of an adjacent locus. Proc Natl Acad Sci USA 1993;90:8697-701.
9. [9] Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-9.
10. INK4B gene deletions in primary leukemia. Blood 1995;86:311-5.
11. [11] Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995;85:2870-6.
12. [12] Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-65.
13. [13] Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996;93:2264-71.
14. [14] Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991;78:1795-802.
15. [15] Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of B-CLL. Leukemia 1994;8:1640-5.
16. [16] Garand R, Moreau A, Rabillard N, et al. Immunophentypic profiles of 691 cases of chronic B-cell lymphoproliferative disorders (CBLPD) in leukemic phase classified according to morphologic (FAB and REAL) criteria. Blood (abstract) 1996;88:241a.
17. [17] Caligaris-Cappio F, Gobbi M, Bofill M, et al. Infrequent normal B-lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982;155:623-8.
18. [18] Stathopoulos G, Elliot EV. Formation of mouse or sheep red-blood-cell rosettes by lymphocytes from normal and leukaemic individuals. Lancet 1974;1:600-1.
19. [19] Catovsky D, Cherchi M, Okos A, et al. Mouse red-cell rosettes in B-lymphoproliferative disorders. Br J Haematol 1976;33:173-7.
20. [20] Ternynck T, Dighiero G, Follezou J, et al. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. Detection and quantitation of light chain determinants. Blood 1974;43:789-95.
21. [21] Dighiero G, Follezou JY, Roisin JP, et al. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. Quantification of light chain determinants in atypical lymphocytic leukemia. Blood 1976;48:559-66.
22. [22] Zhou LJ, Tedder TF. CD19 workshop panel report. In: Schlossman SF, Boumsell L, Gilks W, et al., editors. Leukocyte Typing V. White Cell Differentiation Antigens. New York: Oxford University Press, 1995:507-9.
23. [23] Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B-lymphocytes a new member of the immunoglobulin superfamily. J Immunol 1989;143:712-7.
24. [24] Matsumoto AK, Kopicky-Burd J, Carter RH, et al. Intersections of the complement and immune systems: a signal transduction complex of the B-lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 1991;173:55-64.
25. [25] Bradbury LE, Kansas GS, Levy S, et al. The CD19/CD21 signal transducing complex of human B-lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 1992;149:2841-50.
26. [26] Takahashi S, Doss C, Levy S, et al. TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol 1990;145:2207-13.
27. [27] Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B-lymphocytes. Immunol Today 1994;15:437-41.
28. [28] Barret TB, Shu GL, Draves KE, et al. Signaling through CD19, Fc receptors or transforming growth factor-β: each inhibits the activation of resting human B-cells differently. Eur J Immunol 1990;20:1053-9.
29. [29] Callard RE, Rigley KP, Smith SH, et al. CD19 regulation of human B-cell responses. B-cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulation signal used. J Immunol 1992;148:2983-7.
30. [30] Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B-lymphocytes. Science 1992;256:105-7.
31. [31] Timems W. CD21 workshop panel report. In: Schlossman SF, Boumsell L, Gilks W, et al., editors. Leukocyte Typing V. White Cell Differentiation Antigens. New York: Oxford University Press, 1995:516-8.
32. [32] Aubry JP, Pochon S, Graber P, et al. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992;358:505-7.
33. [33] Jurlander J, de Nully Brown P, Skov PS, et al. Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B-cell chronic lymphocytic leukemia. Leukemia 1995;9:1902-9.
34. 2+ mobilization of chronic lymphocytic leukemia cells. J Immunol 1991;146:1766-72.
35. [35] Lowe J, Brown B, Hardie D, et al. Soluble forms of CD21 and CD23 antigens in the serum in B-cell chronic lymphocytic leukemia. Immunol Lett 1989;20:103-9.
36. [36] Pleiman CM, D'Ambrosio D, Cambier JC. The B-cell antigen receptor complex: structure and signal transduction. Immunol Today 1994;15:393-8.
37. [37] Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-74.
38. [38] Kehrl JH, Muraguchi A, Fauci AS. Human B-cell activation and cell cycle progression. Stimulation with anti-μ and Staphylococcus aureus Cowan strain I. Eur J Immunol 1984;14:115-21.
39. [39] Banchereau J, Briere F, Liu YJ, et al. Molecular control of B-lymphocyte growth and differentiation. Stem Cells 1994;12:278-88.
40. [40] Drexler HG, Brenner MK, Coustan-Smith E, et al. Analysis of signal transduction in B-chronic lymphocytic leukemia cells. Blood 1988;71:1461-9.
41. [41] Lankester AC, van Schijndel GMW, van der School CE, et al. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia cells. Blood 1995;86:1090-7.
42. [42] Karray S, Merle-Beral H, Vazquez A, et al. Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal. Blood 1987;70:1105-10.
43. [43] Michel F, Merle-Beral H, Legac E, et al. Defective calcium response in B-chronic lymphocytic leukemia cells. J Immunol 1993;150:3624-33.
44. [44] Verschuren MCM, Comans-Bitter WM, Kapteijn CAC, et al. Transcription and protein expression of mb-1 and B29 genes in human hematopoietic malignancies and cell lines. Leukemia 1993;7:939-47.
45. [45] Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996;88:1365-74.
46. [46] Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993;81:2475-87.
47. [47] Goodnow CG, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of self-reactive B-lymphocytes in transgeneic mice. Nature 1988;334:676-82.
48. [48] Cooke MP, Heath AW, Shokat KM, et al. Immunoglobulin signal transduction guides the specificty of B-cell - T-cell interactions and is blocked in tolerant self-reactive B-cells. J Exp Med 1994;179:425-38.
49. [49] Fluckiger AC, Rossi JF, Bussel A, et al. Responsiveness of chronic lymphocytic leukemia B-cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992;80:3173-81.
50. [50] Lotz M, Ranheim E, Kipps TJ. Transforming growth factor-β as endogenous growth inhibitor of chronic lymphcocytic leukemia B-cells. J Exp Med 1994;179:999-1004.
51. [51] Thompson AA, Talley JA, Do HN, et al. Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 1997;90:1387-94.
52. [52] Zhou LJ, Tedder TF. CD19 workshop panel report. In: Schlossman SF, Boumsell L, Gilks W, et al., editors. Leukocyte Typing V. White Cell Differentiation Antigens. New York: Oxford University Press, 1995:511-4.
53. [53] Genot E, Valentine MA, Degos L, et al. Hyperphosphorylation of CD20 in hairy cells. Alteration by low molecular weight B-cell growth factor and IFN-α. J Immunol 1991;146:870-8.
54. 2+ conductance found constititively in B-lymphocytes. J Cell Biol 1993;121:1121-32.
55. [55] Tedder TF, Engel P. CD20: a regulator of cell-cycle progresssion of B-lymphocytes. Immunol Today 1994;15:450-4.
56. [56] Reff ME, Carner K, Chambers KS, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
57. [57] Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66.
58. [58] Cabanillas F, Grillo-López AJ, McLaughlin P, et al. Anti-CD20 antibody (MAB), IDEC-C2B8: clearence of bcl-2 t(14;18) positive cells from peripheral blood (PB) and bone marrow (BM) in patients (pts) with relapsed low-grade or follicular lymphoma (LG/F NHL). Blood (abstract) 1996;88 (Suppl 1):91a.
59. [59] McLaughlin P, Cabanillas F, Grillo-López AJ, et al. IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients (pts) with relapsed low-grade or follicular lymphoma (LG/F NHL). Blood (abstract) 1996;88 (Suppl 1):90a.
60. [60] Kehrl JH. CD19 workshop panel report. In: Schlossman SF, Boumsell L, Gilks W, et al., editors. Leukocyte Typing V. White Cell Differentiation Antigens. New York: Oxford University Press, 1995:523-5.
61. [61] Baldini L, Cro L, Cortelezzi A, et al. Immunophenotypes in 'classical' B-cell chronic lymphocytic leukemia. Cancer 1990;66:1738-42.
62. [62] Stamenkovic I, Sgroi D, Aruffo A, et al. The B-lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T-cells and α2,6-sialyltransferase, CD75, on B-cells. Cell 1991;66:1133-44.
63. [63] Law CL, Sidorenko SP, Clark EA. Regulation of lymphocyte activation by the cell-surface molecule CD22. Immunol Today 1994;15:442-9.
64. [64] Pezzutto A, Rabinovitch PS, Dörken B, et al. Role of CD22 human B-cell antigen in B-cell triggering by anti-immunoglobulin. J Immunol 1988;140:1791-5.
65. [65] Otipoby KL, Andersson KB, Draves KE, et al. CD22 regulates thymus-independent responses and the lifespan of B-cells. Nature 1996;384:634-7.
66. [66] Aruffo A, Kanner SB, Scroi D, et al. CD22-mediated stimulation of T-cells regulates T-cell receptor/CD3-induced signaling. Proc Natl Acad Sci USA 1992;89:10242-6.
67. [67] Durie FH, Foy TM, Masters SR, et al. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994;15:406-10.
68. [68] DiSanto P, Bonnefoy JY, Gauchat JF, et al. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993;361:541-3.
69. [69] Korthäuer U, Graf D, Mages HW, et al. Defective expression of CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993;361:539-41.
70. [70] Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-3.
71. [71] Insel R. Disorders of lymphocyte function. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology. Basic Principles and Practice. New York: Churchill Livingstone, 1991:590-3.
72. [72] Knox KA, Gordon J. Protein tyrosine phosphorylation is mandatory for CD40-mediated rescue of germinal center B-cells from apoptosis. Eur J Immunol 1993;23:2578-84.
73. [73] Paris M, Gaskin F, Parsons JT, et al. CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinases Lyn, Fyn, and Syk and the appearance of a 28-kDa tyrosine phosphorylated protein. J Exp Med 1994;179:923-31.
74. [74] Banchereau J, de Paoli P, Valle A, et al. Long-term human B-cell lines dependent on IL-4 and antibody to CD40. Science 1991;251:70-2.
75. [75] Brugnoni D, Rossi G, Tucci A, et al. Study of CD40 ligand expression in B-cell chronic lymphocytic leukemia. Haematologica 1995;80:440-2.
76. [76] Ranheim EA, Kipps TJ. Activated T-cells induce expression of B7/BB1 on normal or leukemic B-cells through a CD40 dependent signal. J Exp Med 1993;177:925-35.
77. [77] Cantwell MJ, Hua T, Pappas J, et al. Acquired CD40-ligand deficiency in patients with B-cell chronic lymphocytic leukemia. Blood (abstract) 1996;88 (Suppl 1):296a.
78. [78] Yellin MJ, Sinning J, Covey LR, et al. T-lymphocyte T-cell - B-cell-activating molecule/CD40-L molecules induce normal B-cells or chronic lymphocytic leukemia B-cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153:666-74.
79. [79] Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B-cells. Blood 1995;85:3556-65.
80. [80] Van Oers MHJ, Pals ST, Evers LM, et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430-6.
81. [81] Kikutani H, Suemura M, Owaki H, et al. Fcε receptor, a specific differentiation marker transiently expressed on mature B-cells before isotype switching. J Exp Med 1986;164:1455-69.
82. [82] Bonnefoy JY, Guillot O, Spits H, et al. The low-affinity receptor for IgE (CD23) on B-lymphocytes is spatially associated with HLA-DR antigens. J Exp Med 1988;167:57-72.
83. [83] Sarfati M, Ishihara H, Delespesse G. CD23 workshop panel report. In: Schlossman SF, Boumsell L, Gilks W, et al., editors. Leukocyte Typing V. White Cell Differentiation Antigens. New York: Oxford University Press, 1995:530-3.
84. [84] Yokota A, Kikutani H, Tanaka T, et al. Two species of human Fcε receptor II (FcεRII/CD23): tissue-specifc and IL-4 specific regulation of gene expression. Cell 1988;55:611-8.
85. [85] Gordon J. B-cell signalling via the C-type lectins CD23 and CD72. Immunol Today 1994;15:411-7.
86. [86] Fournier S, Delespesse G, Rubio M, et al. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 1992;89:1312-21.
87. [87] Fournier S, Yang LP, Delespesse G, et al. The two CD23 isoforms display differential regulation in chronic lymphocytic leukaemia. Br J Haematol 1995;89:373-9.
88. [88] Sarfati M, Bron D, Lagneaux L, et al. Elevation of IgE-binding factors in the serum of patients with B-cell-derived chronic lymphocytic leukemia. Blood 1988;71:94-8.
89. [89] Beguin Y, Lampertz S, De Groote D, et al. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia. Leukemia 1993;7:2019-25.
90. [90] Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996;88:4259-64.
91. [91] Boumsell L, Bernard A, Lepage V, et al. Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T-cells. Eur J Immunol 1978;8:900-4.
92. [92] Christiansen I, Gidlöf C, Wallgren AC, et al. Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 1994;84:3010-6.
93. [93] Defrance T, Vanbervliet B, Durand I, et al. Human IL-4 down-regulates the surface expression of CD5 on normal and leukemic B-cells. Eur J Immunol 1989;19:293-9.
94. [94] Van de Velde H, von Hoegen I, Luo W, et al. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991;351:662-4.
95. [95] Garand R, Robillard N, Bataille R. CD72 is constantly expressed in chronic lymphocytic leukemia and other B-cell proliferative disorders. Leuk Res 1994;18:651-2.
96. [96] Cerutti A, Trentin L, Zambello R, et al. The CD5/CD72 receptor system is coxpressed with several functionally relevant counterstructures on human B-cells and delivers a critical signaling activity. J Immunol 1996;156:1854-62.
97. [97] Lankester AC, van Schijndel GMW, Cordell JL, et al. CD5 is associated with the human B-cell antigen receptor complex. Eur J Immunol 1994;24:812-6.
98. fyn. Proc Natl Acad Sci USA 1992;89:9311-5.
99. [99] Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-51.
100. [100] Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-8.
101. [101] Schindler C, Darnell Jr JE. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann Rev Biochem 1995;64:621-51.
102. [102] Ihle JN, Kerr IM. JAKs and STATs in signaling by the cytokine receptor superfamily. Trends Genet 1995;11:69-74.
103. [103] Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995;268:251-5.
104. [104] Baggiolini M, Dewald B, Moser B. IL-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994;55:97-179.
105. [105] Sadowski HB, Shuai Ke, Darnell JE Jr, et al. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993;261:1739-44.
106. [106] Lai CF, Ripperger J, Morella KK, et al. Receptors for IL-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem 1996;271:13968-75.
107. [107] Reittie JE, Yong KL, Panayiotidis P, et al. IL-6 inhibits apoptosis and tumor necrosis factor induced proliferation of B-chronic lymphocytic leukemia. Leuk Lymphoma 1996;22:83-90.
108. [108] Watson CJ, Miller WR. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 1995;71:840-4.
109. [109] Gouilleux-Gruart V, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996;87:1692-7.
110. [110] Mahajan S, Rudders SA, Ritz J, et al. Lymphocytes from patients with chronic lymphocytic leukemia contain STAT1 and STAT3 constitutively phoshorylated on serine. Blood (abstract) 1996;88 (Suppl 1):296a.
111. [111] Colamonici OR, Neckers LM, Rosolen A. Putative γ-subunit of the IL-2 receptor is detected in low-, intermediate-and high-affinity IL-2 receptor bearing cells. J Immunol 1990;145:155-60.
112. [112] Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993;73:5-8.
113. [113] de Totero D, di Celle PF, Cignetti A, et al. The IL-2 receptor complex: expression and function on normal and leukemic B-cells. Leukemia 1995;9:1425-31.
114. [114] Kondo M, Takeshita T, Ishii N, et al. Sharing of the IL-2 receptor γ-chain between receptors for IL-2 and Il-4. Science 1993;262:1874-7.
115. [115] Russel SM, Keegan AD, Harada N, et al. IL-2 receptor γ-chain: a functional component of the IL-4 receptor. Science 1993;262:1880-3.
116. [116] Noguchi M, Nakamura Y, Russel SM, et al. IL-2 receptor γ-chain: a functional component of the IL-7 receptor. Science 1993;262:1877-80.
117. [117] Kondo M, Takeshita T, Higuchi M, et al. Functional participation of the IL-2 receptor γ-chain in IL-7 receptor complexes. Science 1994;263:1453-4.
118. [118] He YW, Levy RB, Malek TR. Blockade of T-and B-lymphocyte development by antibody to the γc subunit of the receptors for interleukins 2,4 and 7. Proc Natl Acad Sci USA 1995;92:5689-93.
119. [119] Thomis DC, Gurniak CB, Tivol E, et al. Defects in B-lymphocyte maturation and T-lymphocyte activation in mice lacking JAK3. Science 1995;270:794.
120. [120] Yagura H, Tamaki T, Furitsu T, et al. Demonstration of high-affinity IL-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization. Blut 1990;60:181-6.
121. [121] Tsilivakos V, Tsapis A, Kakolyris S, et al. Characterization of IL-2 receptors on B-cell chronic lymphocytic leukemia. Leukemia 1994;8:1571-8.
122. [122] Semenzato G, Foa R, Agostini C, et al. High serum levels of soluble IL-2 receptor in patients with B-chronic lymphocytic leukemia. Blood 1987;70:396-400.
123. [123] Trentin L, Zambello R, Agostini C, et al. Expression and regulation of tumor necrosis factor, IL-2 and hematopoietic growth factor receptors in B-cell chronic lymphcocytic leukemia. Blood 1994;84:4249-56.
124. [124] Fluckiger AC, Garrone P, Durand I, et al. IL-10 (IL-10) up-regulates functional high-affinity IL-2 receptors on normal and leukemic B-lymphocytes. J Exp Med 1993;178:1473-81.
125. [125] Totterman TH, Danersund A, Carlsson M, et al. Effects of recombinant INF-α and -γ on B-CLL cells in serum-free medium: expression of activation, differentiation and CALLA antigens. Leukemia 1987;1:667-79.
126. [126] Zola H, Flego L, Weedon H. Expression of IL-4 receptor on human T-and B-lymphocytes. Cell Immunol 1993;150:149-58.
127. [127] Digel W, Schmid M, Heil G, et al. Human IL-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 1991;78:753-9.
128. [128] Fluckiger AC, Briere F, Zurawski G, et al. IL-13 has only a subset of IL-4-like activities on B-chronic lymphocytic leukaemia cells. Immunol 1994;83:397-403.
129. [129] Trentin L, Cerutti A, Zambello R, et al. IL-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996;87:3327-35.
130. [130] di Celle PF, Carbone A, Marchis D, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive IL-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 1994;84:220-8.
131. [131] Long BW, Witte PL, Abraham GN, et al. Apoptosis and IL-7 gene expression in chronic B-lymphocytic leukemia cells. Proc Natl Acad Sci USA 1995;92:1416-20.
132. [132] Till KJ, Burthem J, Lopez A, et al. Granulocyte-macrophage colony-stimulating factor receptor: stage-specific expression and function on late B-cells. Blood 1996;88:479-86.
133. [133] Mainou-Fowler T, Craig VA, Copplestone JA, et al. IL-5 incrases spontaneous apoptosis of B-cell chronic lymphocytic leukemia cells in vitro independently of bcl-2 expression, and is inhibited by IL-4. Blood 1994;84:2297-304.
134. [134] Hahn T, Shulman L, Karov Y, et al. Involvement of IL-6 in the autocrine stimulation of chronic lymphocytic leukemia B-cells by tumor necrosis factor. Leuk Lymphoma 1991;5:65-9.
135. [135] Aderka D, Maor Y, Novick D, et al. IL-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α or -β. Blood 1993;81:2076-84.
136. [136] Biondi A, Rossi V, Bassan R, et al. Constitutive expression of the IL-6 gene in chronic lymphocytic leukemia. Blood 1989;73:1279-84.
137. [137] Rambaldi A, Bettoni S, Rossi V, et al. Transcriptional and post-transcriptional regulation of IL-1b, IL-6 and TNF-α genes in chronic lymphocytic leukemia. Br J Haematol 1993;83:204-11.
138. [138] Dadmarz R, Cawley JC. Heterogeneity of CLL: high CD23 antigen and α-IFN receptor expression are features of favourable disease and cell activation. Br J Haematol 1988;68:279-82.
139. [139] Xu B, Grander D, Sangfelt O, et al. Primary leukemia cells resistant to α-INF in vitro are defective in the activation of the DNA-binding factor INF-stimulated gene factor 3. Blood 1994;84:1942-9.
140. [140] Buschle M, Campana D, Carding SR, et al. INF-γ inhibits apoptotic cell death in B-cell chronic lymphocytic leukemia. J Exp Med 1993;177:213-8.
141. [141] Sjoberg J, Aguilar-Santelises M, Sjogren AM, et al. IL-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br J Haematol 1996;92:393-400.
142. [142] Knauf WU, Ehlers B, Bisson S, et al. Serum levels of IL-10 in B-cell chronic lymphocytic leukemia. Blood (letter) 1995;86:4382-3.
143. [143] Egle A, Marschitz I, Posch B, et al. IL-10 serum levels in B-cell chronic lymphocytic leukemia. Br J Haematol (letter) 1996;94:210-2.
144. [144] Digel W, Stefanic M, Schoniger W, et al. Tumor necrosis factor induces proliferation of neoplastic B-cells from chronic lymphocytic leukemia. Blood 1989;73:1242-6.
145. [145] Mapara MY, Bargou R, Zugck C, et al. APO-1 mediated apoptosis or proliferation in human chronic B-lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol 1993;23:702-8.
146. [146] Waage A, Liabakk N, Lien E, et al. p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood 1992;80:2577-83.
147. [147] Digel W, Schoniger W, Stefanic M, et al. Receptors for tumor necosis factor on neoplastic B-cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood 1990;76:1607-13.
148. [148] Digel W, Porzsolt F, Schmid M, et al. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B-chronic lymphocytic leukemia. J Clin Invest 1992;89:1690-3.
149. [149] Jabbar SAB, Hoffbrand AV, Wickremasinghe RG. Regulation of transcription factors NF-κB and AP-1 following tumour necrosis factor-α treatment of cells from chronic B-cell leukaemia patients. Brit J Haematol 1994;86:496-504.
150. [150] Drexler HG, Janssen JWG, Brenner MK, et al. Rapid expression of proto-oncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore. Blood 1989;73:1656-63.
151. [151] Foa R, Massaia M, Cardona S, et al. Production of TNF-α by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990;76:393-400.
152. [152] Cordingley FT, Hoffbrand AV, Heslop HE, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988;2:969-71.
153. [153] Adami F, Guarini A, Pini M, et al. Serum levels of TNF-α in patients with B-cell chronic lymphocytic leukemia. Eur J Cancer 1994;30A:1259-63.
154. [154] di Celle PF, Mariani S, Riera L, et al. IL-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 1996;87:4382-9.
155. [155] König A, Menzel T, Lynen S, et al. Basic fibroblastic growth factor (bFGF) up-regulates the expression of bcl-2 in B-cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997;11:258-65.
156. [156] Douglas RS, Capocasale RJ, Lamb RJ, et al. Chronic lymphocytic leukemia B-cells are resistant to the apoptotic effects of transforming growth factor-β. Blood 1997;89:941-7.
157. [157] DeCoteau JF, Knaus PI, Yankelev H, et al. Loss of functional cell surface transforming growth factor-β (TGF-β) type receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997;94:5877-81.
158. [158] Kremer JP, Reisbach G, Nerl C, et al. B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-β. Br J Haematol 1992;80:480-7.
159. [159] Menzel T, Rahman Z, Calleja E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996;87:1056-63.
160. [160] Lagneaux L, Delforge A, Dorval C, et al. Excessive production of transforming growth factor-β by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and IL-6 production. Blood 1993;82:2379-85.
161. [161] Andreef M, Darzynkiewicz Z, Sharpless TK, et al. Discrimination of human leukemia subtypes by flowcytometric analysis of cellular DNA and RNA. Blood 1980;55:282-93.
162. [162] Karray S, Vazquez A, Merle-Beral H, et al. Synergistic effect of recombinant IL-2 and INF-γ on the proliferation of human monoclonal lymphocytes. J Immunol 1987;138:3824-8.
163. [163] Moore JS, Friedman DF, Silberstein LE, et al. Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia. Crit Rev Oncol Hematol 1995;20:141-64.
164. [164] Natarajan S, Kay NE, Yannelli JR. In vitro propagation of anti-tumor lymphocytes derived from the peripheral blood mononuclear cells of patients with B-chronic lymphocytic leukemia. Blood 1996;88 (Suppl 1):589a.
165. [165] Drexler HG. Which cells do respond during in vitro stimulation of B-CLL and HCL cultures? Leukemia (letter) 1988;2:708-9.
166. [166] Carlsson M, Totterman TH, Rosen A, et al. IL-2 and a T-cell hybridoma (MP6) derived B-cell-stimulatory factor act synergistically to induce proliferation and differentiation of human B-chronic lymphocytic leukemia cells. Leukemia 1989;8:593-601.
167. + T-cell line-secreted factor, growth promoting for normal and leukemic B-cells, identified as thioredoxin. Int Immunol 1995;7:625-33.
168. [168] Karray S, DeFrance T, Merle-Béral H, et al. IL-4 counteracts the IL-2 induced proliferation of monoclonal B-cells. J Exp Med 1988;168:85-94.
169. [169] Carlsson M, Sundstrom C, Bengtsson M, et al. IL-4 strongly augments or inhibits DNA synthesis and differentiation of B-type chronic lymphocytic leukemia cells depending on the costimulatory activation and progression signals. Leukemia 1989;19:913-21.
170. [170] Chaouchi N, Wallon C, Goujard C, et al. IL-13 inhibits IL-2 induced proliferation and protects chronic lymphocytic leukemia B-cells from in vitro apoptosis. Blood 1996;87:1022-9.
171. [171] Östlund L, Einhorn S, Robert KH, et al. Chronic B-lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro. Blood 1986;67:152-9.
172. [172] Fluckiger AC, Durand I, Banchereau J. IL-10 induces apoptotic cell death of B-chronic lymphocytic leukaemia cells. J Exp Med 1994;179:91-9.
173. [173] van Cooten C, Rensink I, Aarden L, et al. IL-4 inhibits both paracrine and autocrine tumor necrosis factor-α-induced proliferation of B-chronic lymphocytic leukemia cells. Blood 1992;80:1299-306.
174. [174] Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
175. [175] van Cooten C, Rensink I, Aarden L, et al. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia 1993;7:618-24.
176. [176] Collins RJ, Verschuer LA, Harmon BV, et al. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71:343-50.
177. [177] Green DR, Scott DW. Activation-induced apoptosis in lymphocytes. Curr Opin Immunol 1994;6:476-87.
178. [178] Panayiotidis P, Ganeshaguru K, Foroni L, et al. Expression and function of the FAS antigen in B-chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995;9:1227-32.
179. [179] Mainou-Fowler T, Craig VA, Copplestone AJ, et al. Effect of anti-APO1 on spontaneous apoptosis of B-cells in chronic lymphocytic leukaemia: the role of bcl-2 and IL-4. Leuk Lymphoma 1995;19:301-8.
180. [180] McConkey DJ, Aguilar-Santelises M, Hartzell P, et al. Induction of DNA fragmentation in B-chronic lymphocytic cells. J Immunol 1991;146:1072-6.
181. [181] Dancescu M, Rubio-Trujillo M, Biron G, et al. IL-4 protects chronic lymphocytic leukemic B-cells from death by apoptosis and up-regulates bcl-2 expression. J Exp Med 1992;176:1319-26.
182. [182] Panayiotidis P, Ganeshaguru K, Jabbar SAB, et al. IL-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993;85:439-45.
183. [183] Chaouchi N, Wallon C, Taieb J, et al. INF-α-mediated prevention of in vitro apoptosis of chronic lymphocytic leukemia B-cells: role of bcl-2 and c-myc. Clin Immunol Immunopathol 1994;73:197-204.
184. [184] Jewell AP, Worman CP, Lydyard PM, et al. INF-α up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol 1994;88:268-74.
185. [185] Frankfurt OS, Byrnes JJ, Villa L. Protection from apoptotic death by IL-4 is increased in previously treated chronic lymphocytic leukemia patients. Leuk Res 1997;21:9-16.
186. [186] Rojas R, Roman J, Torres A, et al. Inhibition of apoptotic cell death in B-CLL by INF-γ correlates with clinical stage. Leukemia 1996;10:1782-8.
187. [187] Panayiotidis P, Jones D, Ganeshaguru K, et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97-103.
188. [188] Osorio LM, De Santiago A, Aguilar-Santelises M, et al. CD6 ligation modulates the bcl-2/Bax ratio and protects chronic lymphocytic leukemia B-cells from apoptosis induced by anti-IgM. Blood 1997;89:2833-41.
189. [189] Begleiter A, Lee K, Israels LG, et al. Chlorambucil-induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 1994;8:103-6.
190. [190] Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-b-D-arabinosyl-2-fluoroadenine. Blood 1993;81:143-50.
191. [191] Begleiter A, Wang H, Verburg L, et al. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1996;10:1959-65.
192. [192] Mentz F, Merle-Beral H, Ouaaz F, et al. Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides. Br J Haematol 1995;90:957-9.
193. [193] Mentz F, Mossalayi MD, Ouaaz F, et al. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood 1996;88:2172-82.
194. [194] Pezzella F, Tse AGD, Cordell JL, et al. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990;137:225-32.
195. + B-cells the expression of bcl-2 gene family is shifted towards protection from apoptosis. Br J Haematol 1996;94:612-8.
196. [196] Yang E, Korsmeyer S. Molecular thanatopsis: a discourse on the bcl-2 family and cell death. Blood 1996;88:386-401.
197. [197] Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996;95:513-7.
198. [198] McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of bcl-2 and bax. J Immunol 1996;156:2624-30.
199. [199] Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-62.
200. [200] Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
201. [201] Gartenhaus RB, Wang P, Hoffman M, et al. The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. J Mol Med 1996;74:143-7.
202. [202] Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
203. [203] Bellosillo B, Dalmau M, Colomer D, et al. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 1997;89:3378-84.
204. [204] Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
205. [205] Haupt Y, Maya R, Kazaz A, et al. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
206. [206] Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
207. KIP1 cyclin-dependent kinase inhibitor expression during IL-4 mediated human B-cell activation. J Immunol 1997;158:3054-61.
208. [208] Sangfelt O, Erickson S, Einhorn S, et al. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 1997;14:415-23.
209. WAF1/CIP1 mediated by STAT1. Science 1996;272:719-22.
210. [210] Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996;92:382-8.
211. [211] Que TH, Garcia Marco J, Ellis J, et al. Trisomy 12 in chronic lymphocytic leukemia detected by fluoresecence in situ hybridization: analysis by stage, immunophenotype and morphology. Blood 1993;82:571-5.
212. [212] Escudier SM, Pereira-Leahy JM, Drach JW, et al. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993;81:2702-7.
213. [213] Julliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. New Engl J Med 1990;323:720-4.
214. [214] Crossen PE. Genes and chromosomes in chronic B-cell leukemia. Cancer Genet Cytogenet 1997;94:44-51.
215. [215] Dierlamm J, Michaux L, Criel A, et al. Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications. Cancer Genet Cytogenet 1997;94:27-35.
216. [216] Garcia-Marco J, Matutes E, Morilla R, et al. Trisomy 12 in B-cell chronic lymphocytic leukaemia: assesment of lineage restriction by simultaneous analysis of immunophenotype and genotype in interphase cells by fluorescence in situ hybridization. Br J Haematol. 1994;87:44-50.
217. [217] Tabernero MD, San Miguel JF, Garcia JL, et al. Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. Cytometry 1995;22:217-22.
218. [218] Garcia-Marco JA, Price GM, Ellis J, et al. Correlation of trisomy 12 with proliferating cells by combined immunocytochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia. Leukemia 1996;10:1705-11.
219. [219] Merup M, Juliusson G, Wu X, et al. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukaemia. Eur J Haematol 1997;58:174-80.
220. [220] Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
221. [221] Haidar MA, El-Hajj H, Bueso-Ramos CE, et al. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am J Hematol 1997;54:189-95.
222. [222] Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
223. [223] Avet-Loiseau H, Devilde MC, Garand R, et al. 13q14 deletions are not primary events in B-cell chronic lymphocytic leukemia: a study of 100 patients using fluorescence in situ hybridization. Clin Cancer Res 1996;2:1673-7.
224. [224] Garcia-Marco JA, Caldas C, Price CM, et al. Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia. Blood 1996;88:1568-75.
225. [225] Panayiotidis P, Ganeshaguru K, Rowntree C, et al. Deletion of 13q14.3 and not 13q12 is the most common genetic abnormality detected in CLL cells. Blood (abstract) 1996;88 (Suppl 1):357a.
226. [226] Liu Y, Grander D, Soderhall S, et al. Retinoblastoma gene deletions in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 1992;4:250-6.
227. [227] Kornblau SM, Chen N, del Giglio A, et al. Retinoblastoma protein expresion is frequently altered in chronic lymphocytic leukemia. Cancer Res 1994;54:242-6.
228. [228] Newcomb EW, Thomas A, Selkirk A, et al. Frequent homozygous deletions on D13S218 on 13q14 in B-cell chronic lymphocytic leukemia independent of disease stage and retinoblastoma gene inactivation. Cancer Res 1995;55:2044-7.
229. [229] Liu Y, Hermanson M, Grander D, et al. 13q deletions in lymphoid malignancies. Blood 1995;86:1911-5.
230. [230] Devilder MC, Francois S, Bosic C, et al. Deletion cartography around the D13S25 locus in B-cell chronic lymphocytic leukemia and accurate mapping of the involved tumor suppressor gene. Cancer Res 1995;55:1355-7.
231. [231] Hawthorn L, Roberts T, Verlind E, et al. A yeast artificial chromosome contig that spans the RB1-D13S31 interval on human chromosome 13 and encompasses the frequently deleted region in B-cell chronic lymphocytic leukemia. Genomics 1995;30:425-30.
232. [232] Bullrich F, Veronese ML, Kitada S, et al. Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood 1996;88:3109-15.
233. [233] Geisler CH, Phillip P, Egelund Christensen B, et al. Chromosome 17 abnormalities, and not trisomy 12, are the most important cytogenetic abnormalities for the prognosis of B-cell chronic lymphocytic leukaemia. A cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res (in press).
234. [234] El Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocyctic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-9.
235. [235] Newcomb EW, El Rouby S, Thomas A. Unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. Mol Cacinog 1995;14:227-32.
236. INK4A (9p21) and DBM (13q14)) in B-cell chronic lymphocytic leukemia. Mol Carcinog 1995;14:141-6.
237. [237] Ogawa S, Hangaishi A, Miyakawi S, et al. Loss of cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematoppoietic malignancies. Blood 1995;86:1548-56.
238. [238] Schroder M, Mathieu U, Dreyling MH, et al. CDKN2 gene deletion is not found in chronic lymphoid leukaemis of B-and T-cell origin but is frequent in acute lymphoblastic leukaemia. Br J Haematol 1995;91:865-70.
239. [239] Quesnel B, Preudhomme C, Philippe N, et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995;85:657-63.
240. [240] Coignet LJA, Schuuring E, Kibbelaar RE, et al. Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization. Blood 1996;87:1512-9.
241. [241] Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996;93:11837-41.
242. [242] Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-22.
243. [243] Lishner M, Lalkin A, Klein A, et al. The bcl-1, bcl-2, and bcl-3 oncogenes are involved in chronic lymphocytic leukemia. Detection by fluorescence in situ hybridization. Cancer Genet Cytogenet 1995;85:118-23.
244. [244] Merup M, Spasokoukotskaja T, Einhorn S, et al. Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia. Br J Haematol 1996;92:647-52.
245. [245] Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol 1995;6:219-35.
246. H segments with different hypervariable loops. J Mol Biol 1992;227:776-98.
247. [247] Max EE. Immunoglobulins. Molecular genetics. In: Paul WE, editor. Fundamental Immunology. New York: Raven Press, 1993:315-83.
248. [248] Lin WC, Desiderio S. V(D)J recombination and the cell cycle. Immunol Today 1995;16:279-89.
249. [249] Bröker BM, Klajman A, Youinou P, et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988;1:469-81.
250. [250] Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CDS-expressing lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989;169:255-68.
251. [251] Borche L, Lim A, Binet JL, et al. Evidence that chronic lymphocytic leukemia B-lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990;76:562-9.
252. [252] Levinson AI, Dalai NF, Haidar M, et al. Prominent IgM rheumatoid factor production by human cord blood lymphocytes stimulated in vitro with Staphylococcus aureus Cowan strain I. J Immunol 1987;139:2237-41.
253. [253] Cairns E, St Germain J, Bell DA. The in vitro production of anti-DNA antibody by cultured peripheral blood or tonsillar lymphoid cells from normal donors and SLE patients. J Immunol 1985;135:3839-44.
254. + B-cell subset. Science 1987;236:77-81.
255. [255] Kipps TJ, Robbins BA, Kuster P, et al. Autoantibody-associated cross-reactive idiotypes expressed at high frequency in chronic lymphocytic leukemia relative to B-cell lymphomas of follicular center cell origin. Blood 1988;72:422-8.
256. H1 genes expressed in B-cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997;158:235-46.
257. H genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997;89:4153-60.
258. [258] Tiegs SL, Russel DM, Nemazee D. Receptor editing in self-reactive bone marrow B-cells. J Exp Med 1993;177:1009-20.
259. [259] Hartley SB, Cooke MP, Fulcher DA, et al. Elimination of self-reactive B-lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993;72:325-35.
260. [260] Nossal GJV. Negative selection of lymphocytes. Cell 1994;76:229-39.
261. [261] Cyster JG, Hartley SB, Goodnow CG. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994;371:389-95.
262. H gene and CD5 expression. Blood 1991;78:1503-15.
263. [263] Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 1994;53:114-8.
264. [264] Hansen MM. Chronic lymphocytic leukemia. Clinical studies based on 189 cases followed for a long time. Scand J Haematol 1973;18 (Suppl):1-186.
265. [265] Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994;84:1361-92.
266. 3H-thymidine infusion in two patients. Blood 1973;42:623-36.